<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Open Science Publishers LLP</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">154</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"/><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>LIVER FUNCTIONS DERANGEMENT AMONG SUBSTANCES ABUSERS&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elmorsy</surname><given-names>Ekramy</given-names></name></contrib><contrib contrib-type="author"><name><surname>Salama</surname><given-names>Mohamed Mosad</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abdelsalam</surname><given-names>Mostafa</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nwidu</surname><given-names>Lucky Legbosi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zaki</surname><given-names>Maysaa El Sayed</given-names></name></contrib><contrib contrib-type="author"><name><surname>El-Bendary</surname><given-names>Mahmoud</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anber</surname><given-names>Nahla</given-names></name></contrib><contrib contrib-type="author"><name><surname>Aggour</surname><given-names> Amal Misbah</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>30</day><month>11</month><year>2015</year></pub-date><volume/><issue/><fpage>19</fpage><lpage>26</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>Background: Substance abuse is a worldwide problem with rapidly expanding prevalence. Liver is highly vulnerable to xenobiotics toxicities. Methods: We have investigated the effect of substances of 5 commonly abused in Egypt (tramadol, opiates, cannabis, barbiturates and benzodiazepines) on liver functions in persons attending to Mansoura university hospitals. After exclusion of cases with chronic liver diseases, participants were screened by enzyme multiplied immunoassay. Positive cases were confirmed by gas chromatography-mass spectroscopy and examined by abdominal ultrsonography and live functions tests were done. Results: GC-MS showed only 125 positive cases. No abnormalities were detected by ultrasonography in the examined populations. SGOT, SGPT and direct bilirubin were significantly increased, while albumin was significantly decreased in abusers in comparison to nonabusers. Tramadol and other opioids were shown to be the most hepatotoixc agents. In addition, SGOT was shown to be significantly increased to less extent in tramadol and cannabis co-abusers. Furthermore, benzodiazepines were shown to significantly increase serum direct and total bilirubin. Conclusions: We can conclude that tramadol and other opioids significantly alter liver synthetic and excretory function in parallel to significant increase in liver enzymes among abusers. Moreover, cholestatic hepatitis was observed among benzodiazepine abusers.&#13;
</p></abstract><kwd-group><kwd>Hepatotoxicity</kwd><kwd> Substance abuse</kwd><kwd> Tramadol abuse</kwd><kwd> Liver functions</kwd></kwd-group></article-meta></front></article>
